Citius is dedicated to building a successful pharmaceutical company by partnering to develop and commercialize innovative, efficacious, and cost-effective products that address compelling market opportunities.

To learn more about our capabilities and opportunities for partnership, please contact us at info@citiuspharma.com.

Two of our product candidates have been developed by clinicians and technologists at the MD Anderson Cancer Center. In 2016, Citius acquired a worldwide license for Mino-Lok®, the first and only product in development to salvage infected Central Venous Catheters. In January 2019, Citius acquired a worldwide license for Mino-Wrap, potentially the first and only product for the prevention of infections associated with post-mastectomy implants.

Brooklyn ImmunoTherapeutics Logo

In 2020, we partnered with Novellus Therapeutics Ltd. (acquired by Brooklyn ImmunoTherapeutics, Inc. in July 2021), a Cambridge, Massachusetts-based cell engineering company to create NoveCite Inc., a majority-owned subsidiary of Citius. NoveCite is initially focused on developing, manufacturing and commercializing a unique induced mesenchymal stem cell platform for the treatment of patients with acute respiratory distress syndrome (ARDS), including as a result of COVID-19.